IbnSina Pharma: Annual performance back to norm, base effect shapes sequential performance

  • Retail segment grown on ASP; ISPH outperforms market

  • Revenue growth held back by slow retail growth, despite solid wholesale performance

  • G&A expenses and IFRS16 implementation hold back bottom line, A weak base effect led the sequential surge

Subscribe to read this report

You can read this report by subscribing to a Starter or Pro plan today.

Already have an account? Log in


Access to recommendations is a Pro feature.


This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not constitute investment recommendation, and nor is it investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument.

This publication is not intended for distribution to, or use by, any person or entity in any jurisdiction in any country where such distribution or use would be contrary to law or regulation, or which would subject Tellimer to any registration requirement within such jurisdiction or country.

This research is produced by a third party. The Tellimer team has had no editorial input into the content of the note.